Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials von Lee, Christine, Louie, Thomas, Bancke, Lindy, Guthmueller, Beth, Harvey, Adam, Feuerstadt, Paul, Khanna, Sahil, Orenstein, Robert, Dubberke, Erik R.

Volltext

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection von Dubberke, Erik R., Orenstein, Robert, Khanna, Sahil, Guthmueller, Beth, Lee, Christine

Volltext

Sa1901 EFFICACY AND SAFETY OF FECAL MICROBIOTA, LIVE-JSLM IN PARTICIPANTS WITH RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION RECEIVING CONCOMITANT MEDICATIONS von Tillotson, Glenn S., Feuerstadt, Paul, Carlson, Travis J., Guthmueller, Beth, Martinez, Anthony, Reveles, Kelly

Volltext

700 SAFETY AND EFFICACY OF RBX2660 IN REDUCING RECURRENT CLOSTRIDIOIDES DIFFICILE INFECTION IN IMMUNOCOMPROMISED PARTICIPANTS von Dubberke, Erik R., Fischer, Monika, Tillotson, Glenn S., Bidell, Monique, Guthmueller, Beth, Hoeyer, Frederikke, Alonso, Carolyn D.

Volltext

1042. Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical S... von Braun, Tricia, Guthmueller, Beth, Harvey, Adam J

Volltext

PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides... von Feuerstadt, Paul, Chopra, Teena, Knapple, Whitfield, Van Hise, Nicholas W, Dubberke, Erik R, Baggott, Brian, Guthmueller, Beth, Bancke, Lindy, Gamborg, Michael, Steiner, Theodore S, Van Handel, Daniel, Khanna, Sahil

Volltext

706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent Clostridioides difficile... von Fischer, Monika, Thul, Joan, Guthmueller, Beth, Sandrock, Christian, Van Hise, Nicholas, Tillotson, Glenn S

Volltext

Final Results from a Phase 2 Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection von of, Adis Journals on behalf, R. Dubberke, Erik, Orenstein, Robert, Khanna, Sahil, Guthmueller, Beth, Lee, Christine

Volltext bestellen

Safety of fecal microbiota, live-jslm (REBYOTA) in individuals with recurrent infection: data from five prospective clinical trials von Christine Lee, Thomas Louie, Lindy Bancke, Beth Guthmueller, Adam Harvey, Paul Feuerstadt, Sahil Khanna, Robert Orenstein, Erik R. Dubberke

Volltext

702. Efficacy of Fecal Microbiota, Live-jslm After Receipt of Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label Trial von Reveles, Kelly R, Gonzales-Luna, Anne J, Golan, Yoav, Alonso, Carolyn D, Guthmueller, Beth, Tan, Xing, Bidell, Monique, Pokhilko, Victoria, Crawford, Carl, Skinner, Andrew M

Volltext

Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), Among Patients Exposed to Non–Clostridioides difficile Infection Antibiotics: Post Hoc Subgroup Analysis of a Phase 2 Open-Label... von Reveles, Kelly R, Gonzales-Luna, Anne J, Golan, Yoav, Alonso, Carolyn D, Guthmueller, Beth, Tan, Xing, Bidell, Monique R, Pokhilko, Victoria, Crawford, Carl V, Skinner, Andrew M

Volltext